

Systematic Review

Surgical Methods of Management for Hidradenitis Suppurativa: A Narrative Review

Kevin Nguyen, BBmed, BSci (Chem)¹; Sarah R. Adamson, PGDipSurgAnat (Plas), MBBS^{1,2}; Sally Ng, MBBS, FRACS (Plas)^{1*}

¹Department of Plastic and Reconstructive Surgery, Austin Health, 145 Studley Rd, Heidelberg, Victoria 3084, Australia

²The Royal Women's Hospital, Melbourne, VIC 3052, Australia

*Corresponding author

Sally Ng, MBBS, FRACS (Plas)

Plastic and Reconstructive Surgeon, Austin Health, 145 Studley Rd, Heidelberg, Victoria 3084, Australia; E-mail: sally.ng@austin.org.au

Article information

Received: November 13th, 2022; Revised: December 19th, 2022; Accepted: December 19th, 2022; Published: December 31st, 2022

Cite this article

Nguyen K, Adamson SR, Ng S. Surgical methods of management for hidradenitis suppurativa: A narrative review. *Trichol Cosmetol Open J.* 2022; 5(1): 10-19.

doi: [10.17140/TCOJ-5-118](https://doi.org/10.17140/TCOJ-5-118)

ABSTRACT

Objective

Hidradenitis Suppurativa (HS) is a chronic condition that creates a significant burden on a patient's life, both physical and emotional. While a broad range of medical and dressing treatments exist for HS, surgery is often considered the only curative approach. The aim of this study is to comprehensively review existing and emerging surgical options available for the treatment of HS.

Methods

Using the key phrase "Hidradenitis Suppurativa" and the MeSH terms "surgery or surgical" and "treatment or procedure", a search of the Ovid Medline and Pubmed databases was conducted 2012 to 2022. Forty-eight studies meeting criteria were identified and included in the literature review.

Results

Many methods exist for the treatment of HS and there have been promising small scale series and reports that highlight positive disease and quality-of-life (QoL) outcomes associated with some surgical treatment modalities. Most methods are centred around excision of all diseased tissue followed by varying methods of reconstruction. Some novel methods, such as laser ablation, are also used. Each method has its own strengths and weaknesses. Selection of method is currently made based on a case-by-case basis such as disease severity, disease location and surgeon preference.

Conclusion

Further randomised control trials with larger patient populations are needed to quantify the efficacy and safety of the various surgical methods available. These approaches to treatment hold tremendous potential for improving patient outcomes globally.

Keywords

Hidradenitis suppurativa; Acne inversa; Surgery; Surgical; Treatment; Procedure.

INTRODUCTION

Hidradenitis Suppurativa (HS), also known as acne inversa, is a chronic inflammatory condition that affects millions worldwide.^{1,2} HS is characterised by the development of painful nodules, abscesses and sinus tracts which can become infected and purulent.

Excruciating pain, reduction in range of motion (ROM) and issues with mental health and self-esteem are reported as significant, and detrimental to patient quality-of-life (QoL).³ The severity of HS is most often measured using the Hurley staging system, ranging from I-III. Stage I is characterised by the presence of abscesses without any sinus tracts or scarring. Stage II involves multiple abscesses or sinus tracts existing in a single area. In stage

III, sinus tracts and scarring are interconnected, and multiple abs-

Figure 1. Photos of HS Lesions



(a) Hurley stage I HS with one or possibly two solitary nodules. (b) Hurley stage II HS with multiple abscesses. (c) Hurley stage III HS with diffuse and connected abscesses, sinus tracts and cicatrization.¹

esses occur in the region.¹ Figure 1 describes the different stages of the Hurley staging system.

For mild HS, management is typically conservative in nature, involving topical antiseptic wash or topical antibiotics such as 0.1% clindamycin.⁴ Other options for mild to moderate HS are the use of long course oral antibiotics, or in severe cases, treatment with biological agents such as tumour necrosis factor (TNF) inhibitors adalimumab or infliximab.⁵

Surgery is indicated when HS is not medically responsive and is considered the only definitive treatment for recurrent abscesses and sinus tracts associated with stage II-III HS.⁶ Currently there are a wide range of approaches available, however, there is no consensus on the timing and type of surgery that should be performed. As such, this review aims to critically evaluate the surgical methods of treating HS and their outcomes, as reported in the literature.

METHODS

The Ovid Medline and PubMed databases were used to search for relevant literature. Manuscripts with type I-V⁷ evidence were included. The search phrases used for both databases were as follows:

- (Acne inversa OR hidradenitis suppurativa) AND (surgery OR surgical) AND (management OR treatment) with the following filters applied: Last 10-years, Full text available in English.

Inclusion Criteria

1. The full text was available in English.

2. The literature was published in the last 10 years (2012- current).
3. The article was relevant to the surgical treatment of hidradenitis suppurativa with a surgical treatment defined as “the use of instrumentation or manual methods to make an incision or remove body tissues in the treatment of a pathological process”.
4. The primary outcome of “recurrence of HS after surgery” was reported.

Secondary outcomes assessed in included articles were: surgical complications, restriction in ROM post-surgery and QoL changes post-surgery.


Exclusion Criteria

- The article did not report whether recurrence occurred post-surgery.
- The recurrence rate was not linked to a defined surgery method.
- The article was a review.

RESULTS

The search yielded 326 results, 33 duplicates were removed, and 293 articles underwent title and abstract screening. The title and the abstract were assessed using the inclusion and exclusion criteria and 145 articles were sought for a full text review. Two articles could not be retrieved in English and thus only 143 articles were analysed in the full text review. During the full text review articles were read in full and assessed against the exclusion and inclusion criteria. At the end of this process 48 articles were included in the review. Figure 2 summarises the search.

Figure 2. PRISMA Flow Diagram of the Screening Process Used in this Review



Incision and Drainage/Deroofing Procedures

Incision and drainage (I&D) is typically used in more acute disease lesions either when only abscesses or nodules exist, such as Hurley Stage I disease. After thorough washout of the cavity, the wound is packed with dressings and allowed to heal secondarily.

Deroofing is a procedure in which a superficial portion of a nodule or sinus tract is excised, leaving the floor of the tract or nodule to allow for more rapid re-epithelisation with the wound left to heal by secondary intention. A skin tissue sparing excision and electrosurgical peeling (STEEP) technique is a type of deroof-

ing whereby a HS lesion is removed in a layer-by-layer fashion until the floor of the tracts is left. Table 1 outlines the articles that performed I&D and deroofing procedures included in this review.

Surgical Excision

Surgical excision, either wide or radical, was the most reported surgical treatment. It was typically offered for Hurley Stage II or III disease. The wound was either allowed to heal by secondary intention (SIH), primarily closed, or reconstructed with a skin graft or flap. Wide excision typically detailed excision down to healthy tissue whereas radical excision typically referred to excision down to mus-

Table 1. Summary of Articles that Examined I&D or Deroofing Procedures

Author	Disease Location	Procedure Type	Number of Procedures Performed	Recurrence Rate (mean follow-up time)	Secondary Outcomes Reported
Haoxiang et al ⁸	Axilla	Incision and drainage with hydrogen peroxide wash	8	19% (3-months)	87.5% of patients had postoperative complications
Janse et al ⁹	Axilla	STEEP procedure	16	50% (8.26-months)	62.4% of patients had hyper granulation
Lin et al ¹⁰	Axilla Gluteal	Deroofing and healing by second intention	1	None at 3-months	-
Molina-Leyva et al ¹¹	Gluteal	I&D with punch-trocar-assisted cryoinsufflation	10	30% (6-months)	-
Ravi et al ¹²	Axilla, Gluteal Inguinal	Deroofing, secondary intention healing	129	33% (1-year)	--

Table 2. Summary of Articles Examining PC or SIH Wound Method Post-surgery

Author	Disease Location	Procedure type(s)/ Reconstruction Method(s) Examined	Number of Procedures Performed	Recurrence Rate (mean follow up time)	Secondary Outcomes Reported/Key Findings
Chen et al ¹³	Axilla Groin	Wide excision, immediate PC (n=15) or delayed vacuum assisted PC (n=12)	27	At 3-months Immediate closure: 13% (n=2) Delayed closure: 0%	Immediate closure group had no complications, delayed closure group complication rate was 75%
Deckers et al ¹⁴	Axillary Groin Gluteal/anal	Moderate to severe Galbellar rhytides Wide excision, secondary intention healing	86	At 36-months 51%	Genital region most prone to recurrence
DeFazio et al ¹⁵	Axilla	Wide excision, delayed primary closure +/- biological therapy	Surgery only n=26 Combined therapy n=29	At 10.5-months Surgery only=38.5% Combined therapy=19%	-
Fertitta et al ¹⁶	Axilla, Groin, Gluteal, Inguinal Head and neck	Limited local excision or wide excision, SIH	58	At 15-months Limited excision: 25% Wide excision: 14%	10% complication rate overall
Ezanno et al ¹⁷	Axilla	Radical excision, SIH after negative pressure therapy	36	At 16-months 2%	13.9% complication rate (pain, infection and loss of mobility)
Kofler et al ¹⁸	Axilla, Groin, Gluteal, Inguinal, Chest	Wide excision, secondary intention healing	255	At 57-months 69%	25% of patients experienced at least one surgical complication
Mendes et al ¹⁹	Axilla, Gluteal	Radical excision, PC	2	At 1-year 100%	Complication rate of 85% (mainly wound dehiscence)
Ngaage et al ²⁰	Axilla, Gluteal, Groin	Wide excision, PC	72	At 33-months 30%	30% complication rate
Ovadia et al ²¹	Axilla	Wide excision, PC, or SIH	PC n=56 SIH n=23	At 43-months PC=62.5% SIH=70%	-
Posch et al ²²	Axilla, Gluteal, inguinal	Wide excision, SIH	74	At 1-year 18.9%	47% long term complication rate (mostly pain and scarring)
Ravi et al ¹²	Axilla Gluteal Inguinal	Wide excision, PC or SIH	PC n=53 SIH n=12	At 1-year PC=51% SIH=75%	-
Shavit et al ²³	Axilla	Wide excision, SIH	35	At 14.5-months 18%	-

cle fascia. Table 2 summarises the studies that used primary closure or healing by secondary intention following excision of HS.

Skin Grafting/Flap Reconstruction

Split thickness skin grafts (STSG) were used as a single stage reconstruction or two stage reconstruction with an adjunct such as negative pressure wound therapy (NPWT) or dermal matrices used as bridging treatments prior to definitive skin grafting.²⁴ Table 3 summarises the articles that examined skin grafts as a wound closure method post-surgery.

Multiple tissue flaps have been described to reconstruct various defects. The flaps used were all variations of perforator flaps with different characteristics such as donor site and advancement method. In perforator flap reconstruction, perforator vessels are left intact as the flap is moved to its new location creating

a “pedicle” that connects the donor site with reconstruction site that the flap has been moved to. This type of reconstruction is beneficial in HS cases as it allows for areas with wide defects to be reconstructed. Table 4 summarises the articles reporting flap use as part of the surgical management of HS.

Novel Techniques

Three novel techniques were identified in the literature search. These techniques involved removing diseased tissue using CO₂ lasers using a layer-by-layer approach like the STEEP procedure. Table 5 summarises the articles using novel techniques.

DISCUSSION

There was no standardised treatment protocol for HS. Less invasive methods such as incision and drainage were offered for early

Table 3. Summary of Articles Using Skin Grafts

Author	Disease Location	Procedure type(s)/ Reconstruction Method(s) Examined	Number of Procedures Performed	Recurrence Rate (mean follow up time)	Secondary Outcomes Reported/Key Findings
Ayala et al ²⁵	Axilla Groin Inguinal	Wide excision, split thickness skin graft (STSG) or primary closure	139	STSG: 25% Primary closure: 40%	Axillary HS treatment has the highest success rate and lower infection/complication rate than HS in other areas
Chaffin et al ²⁶	Axilla	Wide excision, delayed STSG with ovine forestomach ECM	6	None at 7-months	Minor wound dehiscence in 1 patient
Chen et al ²⁷	Genitoperineal	Radial excision, STSG (n=4) or local skin flap (n=2)	6	STSG: 25% (n=1) Local skin flap: 0%	-
El-Helou et al ²⁸	Perineal	Radical excision, delayed STSG with Vacuum negative pressure therapy and ECM	1	None at 1-year	-
Ge et al ²⁹	Axilla, Gluteal, Groin, Chest Perineal	Wide excision, delayed STSG with negative pressure wound therapy	12	None at 4-years	-
Gonzaga et al ³⁰	Axilla	Wide excision, delayed STSG with Vacuum negative pressure therapy and ECM	4	None at 23-months	-
Hsiao et al ³¹	Axilla	Wide excision, full thickness skin graft from excised tissue (defatted and lesions removed)	1	None at 8-months	No ROM impairment
Kraft et al ²⁴	Axilla	Wide excision, STSG with NPWT and Dermal regeneration template	7	None at 9-months	- No shoulder ROM impairment - No Complications
Lim et al ³²	Gluteal	Wide excision, delayed STSG with negative pressure therapy	1	None at 1-year	-
Maeda et al ³³	Gluteal	Wide excision, STSG from recycled excised tissue or donor site if needed	18	None at 36-months	-
Mendes et al ¹⁹	Axilla Gluteal	Radical excision, STSG	2	At 1-year 50%	Complication rate of 50% (mainly wound dehiscence)
Ngaage et al ²⁰	Axilla, Gluteal, Groin	Wide excision, STSG	35	At 33-months 23%	29% complication rate
Ovadjia et al ²¹	Axilla	Wide excision, STSG	11	At 43-months 63%	-
Steele et al ³⁴	Axilla, Inguinal	Wide excision, STSG	4	At 1-year 25%	-
Wormald et al ³⁵	Axilla	Wide excision, STSG	12	None at 23-months	25% of patients had ROM restriction
Yamashita et al ³⁶	Axilla Gluteal	Wide excision, delayed STSG with ECM and negative pressure therapy	32	At 12.3-months 3%	50% surgical complication rate (wound dehiscence and infection)

Table 4. Summary of Articles Using Flaps

Author	Disease Location	Procedure type(s)/ Reconstruction Method(s) Examined	Number of Procedures Performed	Recurrence Rate (mean follow up time)	Secondary Outcomes Reported/Key Findings
Alharbi et al ³⁷	Axilla	Wide excision in axilla, VY inner arm flap	10	None at 13-months	- 30% of patients experienced delayed healing - Donor site scars were noticeable, - High axilla ROM
Elboraey et al ³⁸	Axilla	Radical excision, perforator propellor flap from costal region in midaxillary line	8	None at 10-months	- 36% complication rate wound dehiscence (n=2), venous congestion (n=1)
Elgohary et al ³⁹	Axilla	Wide excision, pedicled thoracodorsal perforator flap	28	None at 30-months	- 10% complication rate (bleeding: n=1, wound infection: n=2) - Significant shoulder ROM reported
Fu et al ⁴⁰	Head and neck	Wide excision, perforator forehead flap	1	None at 7-months	-
Hallock ⁴¹	Axilla	Radical excision, VY advancement of thoracodorsal perforator flap	3	None at 9-months	Full range of motion regained post-surgery
Hoang et al ⁴²	Groin	Wide excision, superficial inferior epigastric artery flap from abdominal pannus	1	None at 12-months	-
Marchesi et al ⁴³	Axilla	Wide excision, thoracodorsal perforator flap or latissimus dorsi muscle sparing flap	15	None at 16-months	Early complication rate of 29% (mainly wound dehiscence) and late complication rate of 35% (mostly need for flap debulking)
Marchesi et al ⁴⁴	Axilla Gluteal Inguinal	Wide excision, PC	26	None at 1-year	- Large quality of life increase (DQLI Δ=-16) - Complication rate of 42% (mainly wound dehiscence)
Mendes et al ¹⁹	Axilla, Gluteal	Wide excision, PC, or SIH	25	At 1-year 53%	Complication rate of 60% (mainly wound dehiscence)
Mutaf et al ⁴⁵	Gluteal Sacrococcygeal	Wide excision, SIH	16	None at 36-months	-
Nail-Barthelemy et al ⁴⁶	Axilla	Wide excision, PC or SIH	13	None at 9-months	Maximum angle of shoulder abduction post-surgery=160°
Nesmith et al ⁴⁷	Axilla	Wide excision, SIH	11	None at 4.3-years	-
Ngaage et al ²⁰	Axilla Gluteal Groin	Wide excision, delayed primary closure +/- biological therapy	96	At 33-months 21%	34% complication rate
Oliveria et al ⁴⁸	Intermammary	Limited local excision or wide excision, SIH	1	At 9-months Recurrence in patient	Distal flap tip necrosis occurred
Ovadia et al ⁴⁹	Axilla	Radical excision, SIH after negative pressure therapy	3	None at 43-months	-
Rodriguez et al ⁵⁰	Axilla	Wide excision, secondary intention healing	2	None at 2-months	-
Shavit et al ²³	Axilla	Radical excision, PC	100	At 14.5-months 18%	-
Steele et al ³⁴	Axilla Inguinal	Wide excision, PC	1	None at 1-year	-
Teo et al ⁵¹	Axilla	Wide excision, PC, or SIH	2	None at 11-months	Full shoulder ROM regained
Thomson et al ⁵²	Axilla	Wide excision, SIH	8	None at 15-months	25% surgical complication rate (wound dehiscence and haematoma)
Virág et al ⁵³	Axilla Inguinal Sacrococcygeal	Wide excision, PC or SIH	22	None at 6-months	-
Wormald et al ³⁵	Axilla	Wide excision, SIH	15	At 23-months 7%	Full ROM regained

Table 5. Summary of Articles Examining Novel Techniques

Author	Disease Location	Procedure type(s)/ Reconstruction Method(s) Examined	Number of Procedures Performed	Recurrence Rate (mean follow-up time)	Secondary Outcomes Reported
Abdel Azim et al ⁵⁴	Axilla	Ablation using CO ₂ laser in conjunction with Nd:YAG laser radiation	20	At 3-months CO ₂ and NdYAG laser: 45% Nd:YAG laser only: 80%	-
Hazen et al ⁵⁵	Groin	Excision and marsupialisation using CO ₂ laser	1	None at 18-months	-
Mikkelsen et al ⁵⁶	Axilla	CO ₂ laser evaporation, secondary intention healing	58	At 20.6-months 29%	-

HS (Hurley stage I) and were sometimes paired with the use of hydrogen peroxide or cryoinsufflation with liquid nitrogen. These methods aimed to optimise healing by removing the bacterial load in the area. These treatments were effective in reducing pain and discomfort associated with HS lesions. However, they were also associated with a moderate rate of recurrence (19-30%). It should be noted that there was a small number of articles that reported I&D procedures and as such the recurrence rates are most likely not indicative of all I&D patients.

Deroofing procedures reported recurrence rates of 0 to 30% with the most common complication being post-surgical hyper-granulation.^{9,10} Recurrence in these procedures is thought to be related to unexcised diseased follicles that were either deep to the margins of the deroofing or from sinuses that were not completely deroofed⁹ or from previously normal follicles that have progressed to become diseased after the procedure. The success of deroofing procedures is heavily determined by the ability of the surgeon to identify and deroof all lesions in the area or patient factors such as the severity of HS or complexity of sinus networks. Deroofing appears to be a viable option for patients not suited to or not willing to undergo larger procedures, however, there have not been any large cohort studies examining efficacy, nor have there been any trials comparing it to other surgical methods.

Surgical Excision

Management after excision was varied. Primary closure and healing by second intention were associated with shorter operating time and required less follow-up monitoring, but were associated with high rates of recurrence, with rates between 18% and 75% in larger cohort studies (n>30). The reported complication rates varied significantly between the articles that examined methods using excision and repair with primary closure or healing by second intention. However, the most frequently reported complications were wound infections and post-operative pain.^{12,16,18-22,24} Some proposed reasons for this were that secondary intention healing and primary closure were typically suited to smaller wounds. Limited excision is likely to leave some diseased follicles behind and thus leave a seed for recurrence. However, this has not been proven.

Most of the patients who underwent secondary intention healing or primary closure had HS of Hurley stage I-II and this may be because primary closure (PC) and SIH may not be possible for wide and deep wounds. More severe Hurley stage II or Hurley

stage III HS typically encompass wider areas and have tracts extending deeper into the dermis or adipose tissue of the area and the large wounds left from complete excision of diseased tissue would be difficult to close using PC and may lead to significant restrictions in ROM. Wide excision with SIH or primary closure is most suited to less severe HS or smaller disease areas in regions that are easier to access or where ROM impairment is not as big of a factor.

Skin Grafts

Skin grafts were a commonly reported method of wound closure after wide or radical excision of HS. There were two main methods of skin grafting, immediate or delayed. In some delayed grafting methods, adjunct treatments such as vacuum dressing assisted NPWT, or dermal matrices, were used to aid granulation tissue formation and vascularisation of said tissue before grafting. The aim of this was to improve ROM and aesthetic outcomes by reducing scar contracture. These adjuncts were commonly used in axillary cases of HS where ROM impairment significantly impairs QoL.^{24,26,36}

Most articles examined reported no recurrence of HS post excision and skin graft, however Ovardja et al²¹ and Mendes et al¹⁹ reported recurrence rates of 63% and 50% with samples sizes of 11 and 2 respectively. Similarly to deroofing procedures, it is postured that local recurrence stems from incomplete removal of diseased follicles or from progression of healthy follicles to a diseased state. The most common complication was wound dehiscence, but the rates were highly varied between papers. Overall, skin grafting, especially when used after surgical excision was reported to be an effective treatment for HS with low recurrence and good outcomes functionally (low ROM restriction) and aesthetically, while being appropriate for HS of large areas. Thus, suggesting that these methods could be applied to HS of high severity in most areas of the body. It is noted however that delayed skin grafting with adjuvants requires a high-level of patient adherence, as these methods involve regular wound dressing management or temporary movement restricting braces such as 90-degree abduction shoulder braces to optimise the NWPT or extracellular matrix (ECM) adjuncts. As such, optimal treatment results require discussion on these points to be held before treatment is commenced.

Flap Reconstruction

The aim of using flaps was to allow for large areas of radical exci-

sion to excise as much diseased tissue as possible, while having a method of reconstruction that would be able to close the site and allow for good functional outcomes. Flaps help achieve this goal as having their own blood supply, flaps can be used to cover large areas while also being unlikely to exhibit any contraction and thus are unlikely to impair ROM in the long-term.⁵⁷

The use of flaps does pose some challenges. Procedures involving flaps take significantly longer than other options such as skin grafting and are often more complicated with considerations for the flap donor site, flap blood supply, flap advancement and long-term flap monitoring, needing to be made. Within this study, flaps were typically reported to be used for cases of axillary HS or gluteal/groin HS where the lesion area was large. The flaps used were local or perforator flaps with no free flaps being reported. Recurrence rates were generally low with the majority of articles reporting rates between 0% and 7%, however, a small number of articles reported higher recurrence rates of 18%-53% with moderate patient sample sizes (n=25 to n=100). Complication rates varied with reports ranging from no complications to 42% complication rates post-surgery. Of the reported complications, wound dehiscence and minor flap necrosis were the most reported and highlight the complexities of constructing flaps with adequate blood supply and underlining the need for long-term surveillance of the flap. Positive functional outcomes were widely reported especially in axillary cases of HS. Shoulder ROM was reported to range between 160° of abduction and full ROM post-surgery and the reporting of contracture was rare, occurring along scar lines along the flap's border in some cases but did not significantly hinder ROM. Overall flap reconstruction was effective at preserving ROM and covering areas of wide excision like those found in the treatment of severe HS. Of note however, is the increase in complexity in surgery and treatment follow-up when using flaps.

Novel Techniques

The novel techniques identified revolved around laser ablation or removal of diseased tissue. Hazen et al⁵⁵ and Mikkelsen et al⁵⁶ examined the use of CO₂ laser to ablate diseased tissue while Abdel Azim et al⁵⁴ examined CO₂ laser ablation and Nd:YAG laser treatments. Nd:YAG lasers work by emitting a wavelength or radiation that is highly absorbed by hair follicles and thus theoretically destroys or partially cauterises the follicle. Recurrence rate varied, ranging from 0 to 45% with CO₂ laser treatment, while Nd:YAG monotherapy was reported to have a 80% recurrence rate. A positive characteristic of laser ablation is that the ablation of tissue also provides a haemostatic effect like electrocautery which could be beneficial during treatment of wide areas or areas with a higher bleeding risk.

LIMITATIONS

There were several factors that prevented quantitative comparison between articles reporting different surgical treatment methods. Reporting of outcomes was incredibly varied. There was no standard follow-up time, no standard set of reported outcomes and recurrence rate was often variable even when comparing articles examining similar procedures. Ununiform reporting was further

compounded by the heterogenous nature of HS with differing disease morphology and patient co-morbidities making each case slightly different and not directly comparable to other patients. The inclusion of all articles with evidence levels of type I-V meant that novel and small sample size procedures could be assessed and discussed but also meant that quantitative comparisons would not be reliable. Comparisons between QoL improvement could not be made as this was not widely reported and a common scale for assessing this was not adopted between studies.

CONCLUSION

Surgical management is an effective treatment for HS. It has the potential to be curative even in severe cases of HS. Factors such as surgeon preference, disease severity and patient goals influence what treatment is offered. Despite this, most methods share the same principle of excision of as much diseased tissue as possible. For Hurley Stage I lesions, incision and drainage is the less invasive option that is effective in managing symptoms such as pain. For Hurley Stage II-III lesions, wide excision with reconstruction seems to be a curative option that preserves function of the affected area. However, there are currently no randomised control trials comparing different methods and this is likely due to the heterogeneity of disease morphology and lack of defined treatment algorithm.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. Ovadja ZN, Schuit MM, van der Horst CMAM, Lapid O. Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. *Br J Dermatol*. 2019; 181(2): 344-349 doi: [10.1111/bjd.17588](https://doi.org/10.1111/bjd.17588)
2. Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of hidradenitis suppurativa: A systematic review and meta-regression analysis. *JAMA Dermatol*. 2021; 157(8): 924-931. doi: [10.1001/jamadermatol.2021.1677](https://doi.org/10.1001/jamadermatol.2021.1677)
3. Matusiak Ł. Profound consequences of hidradenitis suppurativa: A review. *Br J Dermatol*. 2020; 183(6): e171-e177. doi: [10.1111/bjd.16603](https://doi.org/10.1111/bjd.16603)
4. Alavi A, Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. *J Am Acad Dermatol*. 2015; 73(5 Suppl 1): S55-S61 doi: [10.1016/j.jaad.2015.07.048](https://doi.org/10.1016/j.jaad.2015.07.048)
5. van Rappard DC, Mekkes JR, Tzellos T. Randomized controlled trials for the treatment of hidradenitis suppurativa. *Dermatol Clin*. 2016; 34(1): 69-80 doi: [10.1016/j.det.2015.08.012](https://doi.org/10.1016/j.det.2015.08.012)
6. Saunte DML, Jemec GBE. Hidradenitis suppurativa: Advances in diagnosis and treatment. *JAMA*. 2017; 318(20): 2019-2032 doi: [10.1001/jama.2017.16691](https://doi.org/10.1001/jama.2017.16691)
7. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and

- their role in evidence-based medicine. *Plast Reconstr Surg*. 2011; 128(1): 305-310 doi: [10.1097/PRS.0b013e318219c171](https://doi.org/10.1097/PRS.0b013e318219c171)
8. Haoxiang X, Chengrang L, Baoxi W, Xinfeng W. Modified abscess drainage in treatment of eight cases with hidradenitis suppurativa in China. *Dermatol Surg*. 2013; 39(5): 779-783 doi: [10.1111/dsu.12110](https://doi.org/10.1111/dsu.12110)
9. Janse IC, Hellinga J, Blok JL, et al. Skin-tissue-sparing excision with electrosurgical peeling: A case series in hidradenitis suppurativa. *Acta Derm Venereol*. 2016; 96(3): 390-391. doi: [10.2340/00015555-2258](https://doi.org/10.2340/00015555-2258)
10. Lin CH, Chang KP, Huang SH. Deroofing: An effective method for treating chronic diffuse hidradenitis suppurativa. *Dermatol Surg*. 2016; 42(2): 273-275. doi: [10.1097/DSS.0000000000000609](https://doi.org/10.1097/DSS.0000000000000609)
11. Molina-Leyva A, Salvador-Rodriguez L, Martinez-Lopez A, Cuenca-Barrales C. Effectiveness, safety and tolerability of drainage and punch-trocar-assisted cryoinflation (cryopunch) in the treatment of inflammatory acute fluid collections in hidradenitis suppurativa patients. *J Eur Acad Dermatol Venereol*. 2019; 33(5): e221-e223. doi: [10.1111/jdv.15406](https://doi.org/10.1111/jdv.15406)
12. Ravi S, Miles JA, Steele C, Christiansen MK, Sayed CJ. Patient impressions and outcomes after clinic-based hidradenitis suppurativa surgery. *JAMA Dermatol*. 2022; 158(2): 132-141. doi: [10.1001/jamadermatol.2021.4741](https://doi.org/10.1001/jamadermatol.2021.4741)
13. Chen YE, Gerstle T, Verma K, Treiser MD, Kimball AB, Orgill DP. Management of hidradenitis suppurativa wounds with an internal vacuum-assisted closure device. *Plast Reconstr Surg*. 2014; 133(3): 370e-377e. doi: [10.1097/PRS.0000000000000080](https://doi.org/10.1097/PRS.0000000000000080)
14. Deckers IE, Dahi Y, van der Zee HH, Prens EP. Hidradenitis suppurativa treated with wide excision and second intention healing: A meaningful local cure rate after 253 procedures. *J Eur Acad Dermatol Venereol*. 2018; 32(3): 459-462 doi: [10.1111/jdv.14770](https://doi.org/10.1111/jdv.14770)
15. DeFazio MV, Economides JM, King KS, et al. Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa. *Ann Plast Surg*. 2016; 77(2): 217-222 doi: [10.1097/SAP.0000000000000584](https://doi.org/10.1097/SAP.0000000000000584)
16. Fertitta L, Hotz C, Wolkenstein P, et al. Efficacy and satisfaction of surgical treatment for hidradenitis suppurativa. *J Eur Acad Dermatol Venereol*. 2020; 34(4): 839-845 doi: [10.1111/jdv.16135](https://doi.org/10.1111/jdv.16135)
17. Ezanno AC, Fougereousse AC, Guillem P, Resoverneuil G. The role of negative-pressure wound therapy in the management of axillary hidradenitis suppurativa. *Int Wound J*. 2022; 19(4): 802-810. doi: [10.1111/iwj.13678](https://doi.org/10.1111/iwj.13678)
18. Kofler L, Schweinzer K, Heister M, Kohler M, Breuninger H, Hafner HM. Surgical treatment of hidradenitis suppurativa: an analysis of postoperative outcome, cosmetic results and quality of life in 255 patients. *J Eur Acad Dermatol Venereol*. 2018; 32(9): 1570-1574. doi: [10.1111/jdv.14892](https://doi.org/10.1111/jdv.14892)
19. Mendes RRdS, Zatz RF, Modolin MLA, Busnardo FDF, Gempelli R. Radical resection and local coverage of hidradenitis suppurativa-acne inversa: Analysis of results. *Rev Col Bras Cir*. 2018; 45(3): e1719. doi: [10.1590/0100-6991e-20181719](https://doi.org/10.1590/0100-6991e-20181719)
20. Ngaage LM, Wu Y, Ge S, et al. Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision. *Int Wound J*. 2020; 17(1): 117-123 doi: [10.1111/iwj.13241](https://doi.org/10.1111/iwj.13241)
21. Ovadia ZN, Bartelink SAW, Hadi K, van de Kar AL, van der Horst C, Lapid O. A multicenter analysis of wide excision and reconstruction for severe anogenital hidradenitis suppurativa. *Ann Plast Surg*. 2021; 86(2): 193-200 doi: [10.1097/SAP.0000000000002554](https://doi.org/10.1097/SAP.0000000000002554)
22. Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K. The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients. *J Am Acad Dermatol*. 2017; 77(1): 123-129.e5. doi: [10.1016/j.jaad.2017.01.055](https://doi.org/10.1016/j.jaad.2017.01.055)
23. Shavit E, Pawliwec A, Alavi A, George R. The surgeon's perspective: A retrospective study of wide local excisions taken to healthy subcutaneous fat in the management of advanced hidradenitis suppurativa. *Can J Surg*. 2020; 63(2): E94-E99. doi: [10.1503/cjs.003119](https://doi.org/10.1503/cjs.003119)
24. Kraft C, Pearson G. Axillary hidradenitis reconstruction using a dermal regeneration template. *Wounds*. 2022; 34(2): 43-46. doi: [10.25270/wnds/110121.01](https://doi.org/10.25270/wnds/110121.01)
25. Ayala D, Dhanasekara CS, Thomas K, et al. Surgical management of advanced hidradenitis suppurativa via a one-stage procedure: A single-center experience. *Am J Surg*. 2020; 220(6): 1462-1466. doi: [10.1016/j.amjsurg.2020.10.004](https://doi.org/10.1016/j.amjsurg.2020.10.004)
26. Chaffin AE, Buckley M-C. Extracellular matrix graft for the surgical management of Hurley stage III hidradenitis suppurativa: A pilot case series. *J Wound Care*. 2020; 29(11): 624-630. doi: [10.12968/jowc.2020.29.11.624](https://doi.org/10.12968/jowc.2020.29.11.624)
27. Chen ML, Odom B, Santucci RA. Surgical management of genitoperineal hidradenitis suppurativa in men. *Urology*. 2014; 83(6): 1412-1417. doi: [10.1016/j.urology.2014.01.011](https://doi.org/10.1016/j.urology.2014.01.011)
28. El-Helou E, Kansoun A, Abi Fadel E, et al. A novel technique for the treatment of a case of verneuil's disease of perineum and axillary regions. *Surg J (N Y)*. 2021; 7(3): e163-e167. doi: [10.1055/s-0041-1731400](https://doi.org/10.1055/s-0041-1731400)
29. Ge S, Orbay H, Silverman RP, Rasko YM. Negative pressure wound therapy with instillation and dwell time in the surgical management of severe hidradenitis suppurativa. *Cureus*. 2018; 10(9): e3319. doi: [10.7759/cureus.3319](https://doi.org/10.7759/cureus.3319)
30. Gonzaga TA, Endorf FW, Mohr WJ, Ahrenholz DH. Novel surgical approach for axillary hidradenitis suppurativa using a bilayer dermal regeneration template: A retrospective case study. *J Burn Care Res*. 2013; 34(1): 51-57 doi: [10.1097/BCR.0b013e31826a7be7](https://doi.org/10.1097/BCR.0b013e31826a7be7)

31. Hsiao SC, Chang CH, Huang SH. Recycled split-thickness skin grafting: A novel treatment for axillary hidradenitis suppurativa. *Dermatol Surg.* 2021; 47(8): 1142-1143 doi: [10.1097/DSS.0000000000002935](https://doi.org/10.1097/DSS.0000000000002935)
32. Lim SYD, Cheong EC, Oon HH. Management of severe hidradenitis suppurativa with biologic therapy and wide excision. *Arch Plast Surg.* 2019; 46(03): 272-276. doi: [10.5999/aps.2018.00339](https://doi.org/10.5999/aps.2018.00339)
33. Maeda T, Kimura C, Murao N, Takahashi K. Promising long-term outcomes of the reused skin-graft technique for chronic gluteal hidradenitis suppurativa. *J Plast Reconstr Aesthet Surg.* 2015; 68(9): 1268-1275. doi: [10.1016/j.bjps.2015.05.025](https://doi.org/10.1016/j.bjps.2015.05.025)
34. Steele AW, Miller NF, Wallace SJ, et al. Hidradenitis suppurativa: A comparison of institutional experience and the tracking operations and outcomes for plastic surgeons registry. *Plast Reconstr Surg.* 2022; 149(5): 1216-1224. doi: [10.1097/PRS.00000000000009024](https://doi.org/10.1097/PRS.00000000000009024)
35. Wormald JC, Balzano A, Clibbon JJ, Figus A. Surgical treatment of severe hidradenitis suppurativa of the axilla: Thoracodorsal artery perforator (TDAP) flap versus split skin graft. *J Plast Reconstr Aesthet Surg.* 2014; 67(8): 1118-1124. doi: [10.1016/j.bjps.2014.04.032](https://doi.org/10.1016/j.bjps.2014.04.032)
36. Yamashita Y, Hashimoto I, Matsuo S, Abe Y, Ishida S, Nakaniishi H. Two-stage surgery for hidradenitis suppurativa: Staged artificial dermis and skin grafting. *Dermatol Surg.* 2014; 40(2): 110-115. doi: [10.1111/dsu.12400](https://doi.org/10.1111/dsu.12400)
37. Alharbi M, Perignon D, Assaf N, Qassemayr Q, Elsamad Y, Sinna R. Application of the inner arm perforator flap in the management of axillary hidradenitis suppurativa. *Ann Chir Plast Esthet.* 2014; 59(1): 29-34. doi: [10.1016/j.anplas.2013.10.005](https://doi.org/10.1016/j.anplas.2013.10.005)
38. Elboracy MA, Alali AB, Alkandari QA. Immediate and delayed reconstruction after excision of axillary hidradenitis suppurativa using a propeller flap. *Plast Reconstr Surg Glob Open.* 2019; 7(8): e2387. doi: [10.1097/GOX.0000000000002387](https://doi.org/10.1097/GOX.0000000000002387)
39. Elgohary H, Nawar AM, Zidan A, Shoulah AA, Younes MT, Hamed AM. Outcome of pedicled thoracodorsal artery perforator flap in the surgical treatment of stage II and III hidradenitis suppurativa of Axilla. *Ann Plast Surg.* 2018; 81(6): 688-693 doi: [10.1097/SAP.0000000000001658](https://doi.org/10.1097/SAP.0000000000001658)
40. Fu S, Fan J, Liu L, et al. Aesthetic mental and cervical reconstruction after severe acne inversa by using a bilateral pedicled expanded forehead flap. *J Craniofac Surg.* 2012; 23(6): e615-e617 doi: [10.1097/SCS.0b013e31826cf6b2](https://doi.org/10.1097/SCS.0b013e31826cf6b2)
41. Hallock GG. Island thoracodorsal artery perforator-based V-Y advancement flap after radical excision of axillary hidradenitis. *Ann Plast Surg.* 2013; 71(4): 390-393 doi: [10.1097/SAP.0b013e31824b3e42](https://doi.org/10.1097/SAP.0b013e31824b3e42)
42. Hoang D, Chen V, Saber S, Patel K, Carey J. Bilateral pedicled superficial inferior epigastric artery flap in the treatment of hidradenitis suppurativa. *Plast Reconstr Surg Glob Open.* 2016; 4(8): e833 doi: [10.1097/GOX.0000000000000847](https://doi.org/10.1097/GOX.0000000000000847)
43. Marchesi A, Marcelli S, Zingaretti N, Parodi PC, Vaienti L. Pedicled thoracodorsal artery perforator and muscle-sparing latissimus dorsi flaps in the axillary reconstruction after hidradenitis suppurativa excision: Functional and aesthetic issues. *Ann Plast Surg.* 2018; 81(6): 694-701. doi: [10.1097/SAP.0000000000001664](https://doi.org/10.1097/SAP.0000000000001664)
44. Marchesi A, Amendola F, Garieri P, Steinberger Z, Vaienti L. Wide local excisions and pedicled perforator flaps in hidradenitis suppurativa: A study of quality of life. *Ann Plast Surg.* 2021; 86(2): 201-205 doi: [10.1097/SAP.0000000000002482](https://doi.org/10.1097/SAP.0000000000002482)
45. Mutaf M, Gunal E, Berberoglu O, Gokce A. Surgical treatment of extensive sacrococcygeal hidradenitis suppurativa with triangular closure technique. *Ann Plast Surg.* 2014; 73(5): 583-587 doi: [10.1097/SAP.0b013e3182840831](https://doi.org/10.1097/SAP.0b013e3182840831)
46. Nail-Barthelemy R, Stroumza N, Qassemayr Q, Delage M, Nassif A, Atlan M. Evaluation of the mobility of the shoulder and quality of life after perforator flaps for recalcitrant axillary hidradenitis. *Ann Chir Plast Esthet.* 2019; 64(1): 68-77. doi: [10.1016/j.anplas.2018.01.003](https://doi.org/10.1016/j.anplas.2018.01.003)
47. Nesmith RB, Merkel KL, Mast BA. Radical surgical resection combined with lymphadenectomy-directed antimicrobial therapy yielding cure of severe axillary hidradenitis. *Ann Plast Surg.* 2013; 70(5): 538-541 doi: [10.1097/SAP.0b013e31828ea7cb](https://doi.org/10.1097/SAP.0b013e31828ea7cb)
48. Oliveira M, Sayed C. Surgical treatment of intermammary hidradenitis suppurativa with a 3-point advancement flap (Mercedes Closure). *Dermatol Surg.* 2020; 46(11): 1457-1460 doi: [10.1097/DSS.0000000000002102](https://doi.org/10.1097/DSS.0000000000002102)
49. EndNote™. !!! INVALID CITATION !!! Web site. <https://community.endnote.com/t/invalid-citation/259536>. Accessed November 11, 2022.
50. Rodriguez JM, Rodriguez F, Rivera D, Naranjo K. Treatment of hidradenitis suppurativa with extensive resection of the lesion and coverage with perforator flaps of the lateral thoracic wall (Lateral Thoracic Artery, Thoracodorsal Artery Perforators). *Plast Reconstr Surg Glob Open.* 2019; 7(2): e2096. doi: [10.1097/GOX.0000000000002096](https://doi.org/10.1097/GOX.0000000000002096)
51. Teo W-L, Ong Y-S, Tan B-K. Radical surgical excision and use of lateral thoracic flap for intractable axillary hidradenitis suppurativa. *Arch Plast Surg.* 2012; 39(06): 663-66. doi: [10.5999/aps.2012.39.6.663](https://doi.org/10.5999/aps.2012.39.6.663)
52. Thomson DR, Saltrese S, Mehdi S. Modified posterior arm flap for axillary hidradenitis suppurativa. *Ann Plast Surg.* 2022; 88(1): 84-87. doi: [10.1097/SAP.0000000000002819](https://doi.org/10.1097/SAP.0000000000002819)
53. Virág TH, Kadar IA, Matei IR, Georgescu AV. Surgical management of hidradenitis suppurativa with keystone perforator island flap. *Injury.* 2020; 51: S41-S47. doi: [10.1016/j.injury.2020.03.025](https://doi.org/10.1016/j.injury.2020.03.025)

54. Abdel Azim AA, Salem RT, Abdelghani R. Combined fractional carbon dioxide laser and long-pulsed neodymium: Yttrium-aluminium-garnet (1064 nm) laser in treatment of hidradenitis suppurativa; a prospective randomized intra-individual controlled study. *Int J Dermatol*. 2018; 57(9): 1135-1144. doi: [10.1111/ijd.14075](https://doi.org/10.1111/ijd.14075)
55. Hazen PG, Daoud S. Scrotal hidradenitis suppurativa with secondary lymphedema and lymphangiomata: Successful management with carbon dioxide laser excision and marsupialization. *Dermatol Surg*. 2015; 41(3): 431-432. doi: [10.1097/DSS.0000000000000302](https://doi.org/10.1097/DSS.0000000000000302)
56. Mikkelsen PR, Dufour DN, Zarchi K, Jemec GB. Recurrence rate and patient satisfaction of CO₂ laser evaporation of lesions in patients with hidradenitis suppurativa: A retrospective study. *Dermatol Surg*. 2015; 41(2): 255-260 doi: [10.1097/DSS.0000000000000264](https://doi.org/10.1097/DSS.0000000000000264)
57. Le Cocq H, Stanley PRW. Closing the gap: Skin grafts and flaps. *Surgery (Oxford)*. 2011; 29(10): 502-506 doi: [10.1016/j.mp-sur.2011.06.021](https://doi.org/10.1016/j.mp-sur.2011.06.021)